RESUMO
BACKGROUND: Thyroid cancer (TC) is a common malignant tumor in the endocrine system. In recent years, the incidence and recurrence rates of TC have been raising due to increasing work pressure and irregular lifestyles. Thyroid-stimulating hormone (TSH) is a specific parameter for thyroid function screening. This study aims to explore the clinical value of TSH in regulating the progression of TC, so as to find a breakthrough for the early diagnosis and treatment of TC. AIM: To explore the value and safety of TSH in the clinical efficacy of patients with TC. METHODS: 75 patients with TC admitted to the Department of Thyroid and Breast Surgery of our hospital from September 2019 to September 2021 were selected as the observation group, and 50 healthy subjects were selected as the control group during the same period. The control group was treated with conventional thyroid replacement therapy, and the observation group was treated with TSH suppression therapy. The soluble interleukin (IL)-2 receptor (sIL-2R), IL-17, IL-35 levels, free triiodothyronine (FT3), free tetraiodothyronine (FT4), CD3+, CD4+, CD8+, CD44V6, and tumor supplied group of factor (TSGF) levels were observed in the two groups. The occurrence of adverse reactions was compared between the two groups. RESULTS: After treatment with different therapies, the levels of FT3, FT4, CD3+, and CD4+ in the observation group and the control group were higher than those before treatment, while the levels of CD8+, CD44V6, and TSGF were lower than those before treatment, and the differences were statistically significant (P < 0.05). More importantly, the levels of sIL-2R and IL-17 in the observation group were lower than those in the control group after 4 wk of treatment, while the levels of IL-35 were higher than those in the control group, and the differences were statistically significant (P < 0.05). The levels of FT3, FT4, CD3 +, and CD4 + in the observation group were higher than those in the control group, and the levels of CD8+, CD44V6, and TSGF were lower than those in the control group. There was no significant difference in the overall incidence rate of adverse reactions between the two groups (P > 0.05). CONCLUSION: TSH suppression therapy can improve the immune function of patients with TC, lower the CD44V6 and TSGF levels, and improve serum FT3 and FT4 levels. It demonstrated excellent clinical efficacy and a good safety profile.
RESUMO
OBJECTIVE: To investigate the correlation between prothrombin G20210A polymorphism and the risk for idiopathic sudden sensorineural hearing loss (ISSNHL) using Meta-analysis methodology. METHODS: Databases, including PUBMED, EMBASE, Cochrane Library and CBM, were searched to collect the case control studies on the correlation between prothrombin G20210A polymorphism and idiopathic sudden sensorineural hearing loss. Only high quality studies were included. All analysis were conducted with Review Manager Version 4.2 software. RESULTS: A total of 9 studies were included, involving 735 cases and 1230 controls. The quality assessment involved 3 parts, 8 scores (totally 8 stars). The results showed the included studies were high-quality. Two studies were 8 stars of quality, three studies were 7 stars, one study was 6 stars, one study was 5 stars, and two studies were 4 stars. Meta-analysis showed that the prothrombin G20210A mutation frequencies of the genotypes and alleles showed significant statistically difference between cases and controls [P = 0.03, OR = 1.79, 95% CI = (1.06, 3.01); P = 0.03, OR = 1.77, 95% CI = (1.06, 2.97), respectively]. CONCLUSIONS: The prothrombin G20210A polymorphism might be a genetic risk factor for sudden hearing loss. However, this conclusion remains to be confirmed by high-quality, large-scale studies.
